New registry explores targeted drug combos for hard-to-treat pancreatic cancer

NCT ID NCT05630989

Recruiting now Knowledge-focused Sponsor: Mandana Kamgar, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. The goal is to see how well these combinations control the cancer and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MEK inhibitor-based combination therapy (with or without hydroxychloroquine or EGFR inhibitor)
What this could lead to: If successful, this could point toward effective treatment strategies for people with this specific KRAS G12R mutation in advanced pancreatic cancer.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove a treatment works. It is early-stage and small (80 people), so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Froedtert Hospital and the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.